Characterizing US Healthcare Delivery in Huntington’s Disease (HD)
Objective: The HD-Net research survey aimed to assess care patterns among practice types in the U.S., to identify gaps in the provision of HD care.…Healthcare utilization in individuals with late onset versus adult-onset Huntington’s disease
Objective: To assess healthcare utilization (HCU) among patients (pts) with late-onset Huntington’s disease (LoHD) versus adult-onset HD (AoHD) and non-HD controls. Background: HD typically manifests…Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease
Objective: Examine healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with late-onset Huntington’s disease (LoHD). Background: Huntington’s disease (HD) is a genetic, neurodegenerative…Primary Palliative Care for Huntington Disease
Objective: To develop a pilot program integrating primary palliative care with interdisciplinary care for Huntington disease (HD). Goals: 1) train HD team members to facilitate…Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders
Objective: We test the hypothesis of modulating subthalamic neuronal firing pattern via injection of hyperpolarizing current as an effective treatment for hyperkinetic movement disorders. Background:…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…Huntington’s disease in Egypt; A big challenge for a mysterious disease
Objective: To identify the challenges of managing Huntington’s disease in Egypt in order to overcome them. Background: Huntington’s disease (HD) is considered a rare disease…Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population
Objective: Compare the marginal healthcare resource utilisation (HRU) and costs between US patients with Huntington’s disease (HD) and non-HD controls. Background: HD is a genetic,…Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience
Objective: To evaluate real-world use and outcomes with deutetrabenazine for Huntington’s disease. Background: Grade A evidence for Huntington’s disease chorea treatment includes tetrabenazine and deutetrabenazine.…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »